For Spain’s billionaire Grifols family, which turned a blood-collection business into one of the world’s largest medical ...
On Wednesday, Grifols SA (NASDAQ:GRFS) said it ended discussions with Brookfield Capital Partners (UK) Limited about a ...
Grifols rejects Brookfield’s €10.5/share offer, signaling undervaluation. Read why GRFS stock is a strong "Buy" despite the ...
The embattled Spanish drugmaker Grifols SA is in talks with banks to refinance about €1.4 billion ($1.48 billion) in bonds ...
The Board of Directors of Grifols (GRFS) announced the termination of discussions with Brookfield Capital Partners UK regarding a ...
Plasma specialist Grifols shrugs off private equity firm Brookfield's potential €6.5B takeover offer
With Spanish plasma specialist Grifols turning down a potential multi-billion-dollar takeover bid, it’s likely back to the ...
Grifols SA’s board of directors said it won’t recommend that shareholders accept Brookfield Asset Management’s indicative ...
PR Newswire • 6 months ago Grifols Celebrates 50 Years of Manufacturing Life-Changing Plasma-Derived Medicines for Patients at Flagship Site in Clayton, N.C. The addition of the Clayton site in ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
The Grifols family won’t support a new bid by a third-party to take its namesake drug-maker private amid indications that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback